CV Therapeutics Readies Ranexa For Launch In March
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending its approval, ranolazine will be supported by 250 sales reps detailing to top prescribing cardiologists.
You may also be interested in...
CVT’s Ranexa Approved For Second-Line Angina
The partial fatty oxidation inhibitor will launch in late March.
CVT’s Ranexa Approved For Second-Line Angina
The partial fatty oxidation inhibitor will launch in late March.
CV Therapeutics Pulls Ranexa Marketing Application In Europe
The firm says it plans to resubmit the application for the chronic angina therapy upon completing “one or several” pharmacokinetic studies.